Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.10.2022 | Case report

Treprostinil

Site pain, drug ineffectiveness and lack of efficacy: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Colglazier E, et al. Safety and tolerability of a rapid transition from intravenous treprostinil to oral selexipag in three adolescent patients with pulmonary arterial hypertension. Journal of Pediatric Pharmacology and Therapeutics 26: 512-516, No. 5, 2021. Available from: URL: https://doi.org/10.5863/1551-6776-26.5.512 Colglazier E, et al. Safety and tolerability of a rapid transition from intravenous treprostinil to oral selexipag in three adolescent patients with pulmonary arterial hypertension. Journal of Pediatric Pharmacology and Therapeutics 26: 512-516, No. 5, 2021. Available from: URL: https://​doi.​org/​10.​5863/​1551-6776-26.​5.​512
Metadaten
Titel
Treprostinil
Site pain, drug ineffectiveness and lack of efficacy: 3 case reports
Publikationsdatum
01.10.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-26785-8

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

AZD 1222

Case report

Secukinumab

Case report

Multiple drugs